| Bioactivity | Valnivudine (FV-100 free base), a prodrug of CF-1743, is an orally active anti-herpes zoster (HZ) nucleoside analogue. CF-1743, a bicyclic nucleoside analog (BCNA), has highly specific antiviral activity against varicella-zoster virus (VZV). Valnivudine is rapidly and extensively converted to CF-1743 in vivo[1][2]. | ||||||||||||
| Invitro | In vitro cytotoxicity studies in normal human primary hepatocytes, keratinocytes, and rapidly dividing HepG2 cells, Valnivudine (FV-100 free base) demonstrates mean 50% cytotoxic concentration values of >10 μM[2]. CF-1743 (compound 4f) has anti-varicella-zoster virus (VZV) activity in VZV OKA (EC50=0.3 nM), VZV YS (EC50=0.1 nM) in HEL cell[3]. | ||||||||||||
| Name | Valnivudine | ||||||||||||
| CAS | 956483-02-6 | ||||||||||||
| Formula | C27H35N3O6 | ||||||||||||
| Molar Mass | 497.58 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Valnivudine
CAS: 956483-02-6 F: C27H35N3O6 W: 497.58
Valnivudine (FV-100 free base), a prodrug of CF-1743, is an orally active anti-herpes zoster (HZ) nucleoside analogue. C
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.